NYU Sells Part of its Remicade Royalty | Chemical & Engineering News
Volume 85 Issue 20 | p. 23 | Concentrates
Issue Date: May 14, 2007

NYU Sells Part of its Remicade Royalty

Department: Business

New York University has sold a portion of its royalty interest in the arthritis drug Remicade to Royalty Pharma, a New York City-based firm that buys revenue-producing intellectual property. NYU will receive $650 million in cash plus additional payments should Remicade, marketed by Johnson & Johnson, exceed certain sales milestones. NYU retains the portion of the royalty payable to the university researchers who developed the monoclonal antibody. Royalty Pharma also has royalty interests in drugs such as Abbott Laboratories' Humira, Amgen's Neupogen, and Genentech's Rituxan.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment